COMMUNIQUÉS West-GlobeNewswire

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
20/03/2025
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, [...]
NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
20/03/2025
Des données évaluant la sécurité et les premiers signes d’efficacité, y compris la mise à jour de la survie sans progression (SSP) locale, issues de la partie escalade de dose achevée d’une étude de Phase 1 sur la ré- [...]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
20/03/2025
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: [...]
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
20/03/2025
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, [...]
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
20/03/2025
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
20/03/2025
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial [...]
Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information
20/03/2025
WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release [...]
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
20/03/2025
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial [...]
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
20/03/2025
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of [...]
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
20/03/2025
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in [...]
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
20/03/2025
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer Advancing [...]
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
20/03/2025
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person [...]
Editas Medicine Announces Chief Financial Officer Transition
20/03/2025
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a [...]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
20/03/2025
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data [...]
Solésence To Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call
20/03/2025
ROMEOVILLE, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
20/03/2025
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved [...]
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
20/03/2025
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with [...]
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
20/03/2025
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
20/03/2025
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized [...]

Pages